Daniel Bauer is a physician-scientist whose research focuses on functional genomics to dissect determinants of blood cell development and disease and develop innovative therapies. He discovered therapeutic genome editing of the BCL11A erythroid enhancer as a favorable strategy for the β-hemoglobinopathies, now validated in several clinical trials, as well as identified a therapeutic gene editing approach for amelioration of ELANE-mutant congenital neutropenia. His clinical work focuses on non-malignant hematology. He is Director of the Gene Therapy Program at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and Donald S. Fredrickson, MD Associate Professor of Pediatrics at Harvard Medical School.